The purpose was to explore cyclicity of breast tenderness and vasomotor symptoms in menstruating mid-life women using the Daily Perimenopause Diary.
Methods
Untreated mid-life women from a convenience sample completed the Daily Perimenopause Diary for clinical (n = 14) or research (n = 10) assessments. Breast tenderness, sleep disturbance and day and night vasomotor intensity were rated on a 0-4 scale with vasomotor number as a count. Daily oral temperature data were analyzed using the Quantitative Basal Temperature algorithm to assess ovulation and estimate luteal phase length. Analysis of variance tested cyclicity using the mean of three 3-day windows (during flow, at mid-cycle and premenstrually).
Results
Ninety-eight complete flow-to-flow diaries (from 24 women, mean age 47 years, cycle length 27 +/- 6.4 (standard deviation) days) were available, with quantitative temperature data for 60 cycles in 16 women. Of assessed cycles, 90% were ovulatory; 25% had luteal phases < 10 days. Breast tenderness was maximal in the premenstrual window overall (p < 0.0001) and in the ovulatory subset. Night sweats were maximal premenstrually (p = 0.0035) except in anovulatory cycles. Daytime flushes were not cyclic (p = 0.1333) except in ovulatory cycles (p = 0.031).
Conclusion
Daily Perimenopause Diaries from mid-life women show premenstrual increases in breast tenderness and night sweats.
Prior JC perimenopause breast tenderness cyclicity, night vasomotor symptoms mid-life menstruating women, Daily Perimenopause Diary symptom tracking, luteal phase length perimenopausal ovulation assessment, premenstrual night sweats perimenopause ovulatory cycles, quantitative basal temperature algorithm ovulation detection, short luteal phase perimenopause breast tenderness, anovulatory cycles vasomotor symptoms perimenopause, Hale Hitchcock Prior perimenopause diary study, mid-life women cyclic symptoms hot flashes breast tenderness
Cite this article
Hale, G. E., Hitchcock, C. L., Williams, L. A., Vigna, Y. M., & Prior, J. C. (2003). Cyclicity of breast tenderness and night-time vasomotor symptoms in mid-life women: information collected using the Daily Perimenopause Diary. *Climacteric : the journal of the International Menopause Society*, *6*(2), 128-139.
Hale GE, Hitchcock CL, Williams LA, Vigna YM, Prior JC. Cyclicity of breast tenderness and night-time vasomotor symptoms in mid-life women: information collected using the Daily Perimenopause Diary. Climacteric. 2003;6(2):128-139.
Hale, G. E., et al. "Cyclicity of breast tenderness and night-time vasomotor symptoms in mid-life women: information collected using the Daily Perimenopause Diary." *Climacteric : the journal of the International Menopause Society*, vol. 6, no. 2, 2003, pp. 128-139.
Panay N et al., 2024
Open Access
Climacteric : the Journal of the International Menopause Society
STUDY Question: How should premature/primary ovarian insufficiency (POI) be diagnosed and managed, based on the best available evidence from published literature?
SUMMARY ANSWER: The current guidelin...
Perimenopause/Menopause > Premature Ovarian Insufficiency > Diagnosis and ManagementReproductive Endocrinology > Ovarian Function > Premature Ovarian FailurePerimenopause/Menopause > Hormone Therapy > POI Treatment Guidelines
Gompel A et al., 2023Climacteric : the Journal of the International Menopause Society
A recent Perspective article asserted that progesterone secretion during ovulatory cycles is the cause of breast cancer. However, we challenge most of the evidence developed in this publication. First...
Reproductive Endocrinology > Progesterone > Breast Cancer RiskMenstrual Cycle > Ovulatory Disturbances > Cancer Risk AssessmentEthics/Philosophy > Scientific Debate > Progesterone Safety Evidence
Prior JC, 2018Climacteric : the Journal of the International Menopause Society
This review's purpose is to highlight evidence that oral micronized progesterone (progesterone) is effective for hot flushes and night sweats (vasomotor symptoms, VMS), improves sleep and is likely sa...
Prior JC, 2018
Open Access
Climacteric : the Journal of the International Menopause Society
Estradiol (E2) is women's dominant 'bone hormone' since it is essential for development of adolescent peak bone mineral density (BMD) and physiological levels prevent the rapid (3-week) bone resorptio...
Bone Health > Osteoporosis Prevention > Progesterone TherapyReproductive Endocrinology > Progesterone > Bone FormationMenstrual Cycle > Ovulatory Disturbances > Bone Mineral Density Impact